I don't think DPI lists competitors in the quarterly
reports (hmmm, might be time to read one again) but
as of 2003 they had this: I don't remember coming across
Cerep, Mimotopes or Biofocus.
º Assay development and screening, including Cerep, Evotec OAI AG, Pharmacopeia and Tripos;
º Combinatorial chemistry instruments, including Argonaut and Mimotopes;
º Compound libraries and lead optimization, including Albany Molecular Research, Pharmacopeia, Array Biopharma, Evotec OAI AG, Biofocus and ArQule;
º Informatics, including Accelrys and Tripos; and
º Gene profiling, including Affymetrix and Gene Logic.
That is right--I don't see any specific competitors mentioned
in the current report.
Ha, this risk is amusing--Our stock price will likely be volatile. Only 3000 shares traded today--lately the
stock is often very thinly traded, but certainly not
volatile today. Sort of an interesting combination for
a change. For awhile it looked sorta daytradable from
3.2 to 3.4. But not today.
edit, Cerep and Mimotopes are indeed on a list:
Message 21749240
edit, Biofocus was Nigel's number one pick for the
contest, but I see by the chart the buyout only
brought the shareprice back to about even for the year. |
